Im vergangenen Jahr erzielte Valneva SE für sein leistungsstärkstes Segment, IXIARO, Einnahmen von 98.42M USD. Die Region United States leistete den größten Beitrag mit 53.61M USD im letzten Jahr.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

IXIARO

DUKORAL

Third party products

R&D

IXCHIQ

Unallocated

Others

Chikungunya VLA1553

COVID VLA2001

Services related to clinical trial material

Lyme VLA15

JEV® product

Leasing revenue

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

IXIARO

98.42M(58.36%)

94.07M(56.98%)

73.48M(48.43%)

41.37M(13.13%)

45.12M(12.96%)

48.48M(43.94%)

--(--)

DUKORAL

31.91M(18.92%)

32.30M(19.57%)

29.77M(19.62%)

17.34M(5.50%)

2.44M(0.70%)

13.30M(12.06%)

31.47M(24.94%)

Third party products

19.16M(11.36%)

33.19M(20.10%)

35.67M(23.51%)

26.55M(8.43%)

15.44M(4.44%)

4.16M(3.77%)

3.90M(3.09%)

R&D

9.98M(5.92%)

--(--)

IXCHIQ

8.42M(4.99%)

--(--)

Unallocated

653.00K(0.39%)

704.00K(0.43%)

1.01M(0.67%)

--(--)

Others

87.00K(0.05%)

1.13M(0.69%)

3.09M(2.04%)

-42.66M(-13.54%)

4.25M(1.22%)

11.81M(10.71%)

-4.75M(-3.76%)

Chikungunya VLA1553

--(--)

3.70M(2.24%)

2.73M(1.80%)

5.57M(1.77%)

3.26M(0.94%)

--(--)

COVID VLA2001

--(--)

5.69M(3.75%)

309.58M(98.26%)

253.31M(72.77%)

--(--)

Services related to clinical trial material

--(--)

275.00K(0.18%)

3.21M(1.02%)

10.00M(2.87%)

--(--)

Lyme VLA15

--(--)

-45.87M(-14.56%)

14.27M(4.10%)

32.57M(29.52%)

--(--)

JEV® product

--(--)

94.31M(74.73%)

Leasing revenue

--(--)

1.27M(1.01%)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

Canada

Germany

France

Nordics

Other Europe

United Kingdom

Austria

Other markets

Other Europe

North America

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

53.61M(30.69%)

48.59M(28.66%)

32.96M(21.45%)

-23.80M(-6.60%)

54.79M(15.78%)

68.36M(82.28%)

63.99M(51.22%)

42.46M(37.56%)

35.82M(34.02%)

--(--)

Canada

30.13M(17.25%)

32.32M(19.06%)

28.19M(18.34%)

18.90M(5.24%)

4.23M(1.22%)

8.96M(10.79%)

24.40M(19.53%)

22.38M(19.79%)

20.49M(19.46%)

--(--)

Germany

17.47M(10.00%)

18.37M(10.84%)

13.50M(8.78%)

68.53M(19.01%)

966.00K(0.28%)

--(--)

France

14.67M(8.40%)

7.22M(4.26%)

5.87M(3.82%)

46.52M(12.91%)

--(--)

3.72M(3.80%)

3.77M(4.52%)

4.84M(11.42%)

5.34M(14.83%)

2.23M(65.02%)

2.71M(26.44%)

Nordics

13.90M(7.96%)

13.94M(8.22%)

12.70M(8.26%)

12.01M(3.33%)

2.44M(0.70%)

2.87M(3.46%)

11.03M(8.83%)

11.62M(10.28%)

10.57M(10.04%)

--(--)

Other Europe

13.88M(7.95%)

--(--)

22.79M(20.16%)

23.86M(22.67%)

40.91M(41.79%)

39.15M(46.98%)

16.84M(39.70%)

12.16M(33.78%)

613.00K(17.87%)

7.55M(73.56%)

United Kingdom

12.64M(7.24%)

19.49M(11.49%)

20.27M(13.18%)

181.13M(50.24%)

256.07M(73.76%)

2.89M(3.47%)

8.61M(6.89%)

8.15M(7.21%)

8.11M(7.70%)

--(--)

Austria

9.47M(5.42%)

15.90M(9.37%)

14.58M(9.49%)

21.11M(5.86%)

17.72M(5.10%)

--(--)

Other markets

8.90M(5.09%)

4.69M(2.77%)

16.31M(10.61%)

17.36M(4.82%)

4.68M(1.35%)

--(--)

4.87M(3.90%)

5.65M(5.00%)

6.44M(6.11%)

--(--)

Other Europe

--(--)

9.06M(5.34%)

9.34M(6.07%)

18.74M(5.20%)

6.29M(1.81%)

--(--)

12.02M(9.62%)

--(--)

North America

--(--)

48.61M(49.65%)

33.93M(40.72%)

19.16M(45.16%)

18.05M(50.17%)

335.00K(9.76%)

--(--)

Other

--(--)

4.65M(4.75%)

6.49M(7.78%)

1.58M(3.72%)

440.00K(1.22%)

252.00K(7.34%)

--(--)